Issue link: https://beckershealthcare.uberflip.com/i/613323
©2015 Pacira Pharmaceuticals, Inc., Parsippany, NJ 07054 PP-EX-US-0758 05/15 The clinical benefi t of the decrease in opioid consumption has not been demonstrated. EXPAREL is indicated for single-dose administration into the surgical site to produce postsurgical analgesia. Important Safety Information EXPAREL is contraindicated in obstetrical paracervical block anesthesia. EXPAREL has not been studied for use in patients younger than 18 years of age. Non-bupivacaine-based local anesthetics, including lidocaine, may cause an immediate release of bupivacaine from EXPAREL if administered together locally. The administration of EXPAREL may follow the administration of lidocaine after a delay of 20 minutes or more. Other formulations of bupivacaine should not be administered within 96 hours following administration of EXPAREL. Monitoring of cardiovascular and neurological status, as well as vital signs should be performed during and after injection of EXPAREL as with other local anesthetic products. Because amide-type local anesthetics, such as bupivacaine, are metabolized by the liver, EXPAREL should be used cautiously in patients with hepatic disease. Patients with severe hepatic disease, because of their inability to metabolize local anesthetics normally, are at a greater risk of developing toxic plasma concentrations. In clinical trials, the most common adverse reactions (incidence ≥10%) following EXPAREL administration were nausea, constipation, and vomiting. Studies demonstrating the safety and effi cacy of EXPAREL were conducted in hemorrhoidectomy and bunionectomy; EXPAREL has not been demonstrated to be safe and effective in other procedures. Please see brief summary of Prescribing Information on reverse side. For more information, please visit www.EXPAREL.com or call 1-855-RX-EXPAREL (793-9727). Data on fi le. Parsippany, NJ: Pacira Pharmaceuticals, Inc.; February 2015. Used in more than 1 MILLION PATIENTS since 2012 Experience the impact: Reduce the need for opioids while providing long-lasting postsurgical pain control—all from a single dose. With EXPAREL, we are able to deliver pain relief without catheters or pumps, and our opioid use has greatly decreased. — Stephan J. Finical, MD Charlotte, North Carolina